These include, for example, CCL19/CCL21, which promote tertiary lymphoid structures and enhance dendritic and T cell recruitment43,44; IL-12, IL-15, and IL-18, which drive Th1 polarization and NK/CD8+ T cell activation45–47; GM-CSF and Flt3L, which expand and mobilize antigen-presenting cells48,49; type I interferons, which activate dendritic cells and improve antigen cross-priming50; and LIGHT (TNFSF14), which normalizes tumour vasculature and facilitates lymphocyte entry51. This evidence concerns the gene CSF2 and neoplasm.